|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
104,690,000 |
Market
Cap: |
107.21(B) |
Last
Volume: |
378,341 |
Avg
Vol: |
759,306 |
52
Week Range: |
$692.45 - $1071.19 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
S&P SMALLCAP 600 |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 150 |
Guru Rank Value : 6.9 |
Guru Occurances : 2 |
|
|
|
|
|
|
|
Company Profile Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Co.'s products include: EYLEA (aflibercept) Injection, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion, myopic choroidal neovascularization, diabetic retinopathy, and neovascular glaucoma; REGEN-COV, which is used for the treatment of COVID-19; and Kevzara (sarilumab) Solution for Subcutaneous Injection, which is used for the treatment of rheumatoid arthritis.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) ![](../../images/information.jpg) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
191,758 |
236,826 |
311,409 |
468,643 |
Total Sell Value |
$188,359,854 |
$231,314,072 |
$294,701,490 |
$404,818,815 |
Total People Sold |
7 |
13 |
16 |
18 |
Total Sell Transactions |
16 |
39 |
65 |
127 |
End Date |
2024-04-04 |
2024-01-02 |
2023-07-04 |
2022-07-04 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Aberman Michael S |
VP Strategy and Investor Relat |
|
2012-11-29 |
4 |
OE |
$24.00 |
$200,016 |
D/D |
8,334 |
18,834 |
|
- |
|
Vagelos P Roy |
Chairman of the Board |
|
2012-11-29 |
4 |
AS |
$175.95 |
$14,111,468 |
D/D |
(78,630) |
56,946 |
|
- |
|
Sing George L |
Director |
|
2012-11-29 |
4 |
S |
$185.00 |
$925,000 |
D/D |
(5,000) |
122,772 |
|
- |
|
Vagelos P Roy |
Chairman of the Board |
|
2012-11-28 |
4 |
AS |
$175.03 |
$1,225,910 |
D/D |
(7,004) |
135,576 |
|
- |
|
Roberts William |
VP Regulat Dev & Med Safety |
|
2012-11-27 |
4 |
GD |
$0.00 |
$0 |
I/I |
11,500 |
17,447 |
|
- |
|
Roberts William |
VP Regulat Dev & Med Safety |
|
2012-11-27 |
4 |
GA |
$0.00 |
$0 |
I/I |
11,500 |
11,500 |
|
- |
|
Vagelos P Roy |
Chairman of the Board |
|
2012-11-27 |
4 |
AS |
$175.19 |
$6,353,788 |
D/D |
(36,246) |
142,580 |
|
- |
|
Vagelos P Roy |
Chairman of the Board |
|
2012-11-26 |
4 |
AS |
$175.12 |
$4,992,146 |
D/D |
(28,507) |
178,826 |
|
- |
|
Baker Charles A |
Director |
|
2012-11-26 |
4 |
AS |
$171.45 |
$2,607,986 |
D/D |
(15,000) |
9,590 |
|
- |
|
Baker Charles A |
Director |
|
2012-11-26 |
4 |
OE |
$9.17 |
$137,550 |
D/D |
15,000 |
10,690 |
|
- |
|
Vagelos P Roy |
Chairman of the Board |
|
2012-11-23 |
4 |
D |
$175.00 |
$28,369,775 |
D/D |
(162,113) |
207,333 |
|
- |
|
Vagelos P Roy |
Chairman of the Board |
|
2012-11-23 |
4 |
OE |
$19.43 |
$6,071,875 |
D/D |
312,500 |
369,446 |
|
- |
|
Terifay Robert J |
SVP Commercial |
|
2012-11-23 |
4 |
S |
$173.90 |
$1,699,970 |
D/D |
(9,745) |
9,372 |
|
- |
|
Goldberg Murray A |
SVP Fin & Admin CFO Asst Secy |
|
2012-11-21 |
4 |
GD |
$0.00 |
$0 |
D/D |
250 |
83,727 |
|
- |
|
Terifay Robert J |
SVP Commercial |
|
2012-11-21 |
4 |
D |
$173.83 |
$1,782,627 |
D/D |
(10,255) |
19,117 |
|
- |
|
Terifay Robert J |
SVP Commercial |
|
2012-11-21 |
4 |
OE |
$16.80 |
$336,000 |
D/D |
20,000 |
29,372 |
|
- |
|
Stahl Neil |
SVP Res and Devel Sciences |
|
2012-11-21 |
4 |
S |
$173.80 |
$4,245,442 |
D/D |
(24,357) |
59,121 |
|
- |
|
Stahl Neil |
SVP Res and Devel Sciences |
|
2012-11-20 |
4 |
D |
$167.17 |
$5,039,005 |
D/D |
(30,143) |
83,478 |
|
- |
|
Stahl Neil |
SVP Res and Devel Sciences |
|
2012-11-20 |
4 |
OE |
$16.80 |
$915,600 |
D/D |
54,500 |
104,219 |
|
- |
|
Vagelos P Roy |
Chairman of the Board |
|
2012-11-19 |
4 |
S |
$160.59 |
$5,219,974 |
I/I |
(32,500) |
127,500 |
|
- |
|
Sing George L |
Director |
|
2012-11-16 |
4 |
S |
$152.00 |
$760,000 |
D/D |
(5,000) |
127,772 |
|
- |
|
Schleifer Leonard S |
President & CEO |
|
2012-11-16 |
4 |
D |
$150.51 |
$5,653,457 |
D/D |
(37,562) |
301,358 |
|
- |
|
Schleifer Leonard S |
President & CEO |
|
2012-11-16 |
4 |
OE |
$111.01 |
$4,857,465 |
D/D |
43,757 |
338,920 |
|
- |
|
Van Plew Daniel P |
SVP & General Mgr Industrial O |
|
2012-11-16 |
4 |
S |
$153.48 |
$2,917,899 |
D/D |
(18,741) |
4,784 |
|
- |
|
Goldberg Murray A |
SVP Finance and Admin CFO Trea |
|
2012-11-14 |
4 |
AS |
$147.65 |
$467,954 |
D/D |
(3,156) |
83,977 |
|
- |
|
2433 Records found
|
|
Page 67 of 98 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|